SavedAdd your journal

Journals / Okmeydanı Tıp Dergisi / 2015 / Cilt: 31 - Sayı: 0

Diabetes Mellitus and Ophthalmology

Diabetes Mellitus ve Oftalmoloji

Burak ERDEN
Selim BÖLÜKBAŞI
Serkan ERDENÖZ
Mustafa ELÇİOĞLU
Pages
12–16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

If diabetic patients can be followed up by an ophthalmologist in proper intervals, visual loss can be prevented using diagnostic and therapeutic tools in a prophylactic fashion

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetes Mellitus and OphthalmologyDiabetes mellitus, being a systemic cronic metabolic disease with its microangiopathic character, can cause several pathologies in various eye tissues.
📊
Key Findings & Data:It can change corneal surface and lacrimal system, it can lead to refractive changes of the cristalline lens or eventully to cataract progression and it can cause severe visual loss secondary to maculopathy or retinopathy in retinal tissue.
💡
Conclusion & Impact:If diabetic patients can be followed up by an ophthalmologist in proper intervals, visual loss can be prevented using diagnostic and therapeutic tools in a prophylactic fashion
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diabetes Mellitus and OphthalmologyDiabetes mellitus, being a systemic cronic metabolic disease with its microangiopathic character, can cause several pathologies in various eye tissues. It can change corneal surface and lacrimal system, it can lead to refractive changes of the cristalline lens or eventully to cataract progression and it can cause severe visual loss secondary to maculopathy or retinopathy in retinal tissue. If diabetic patients can be followed up by an ophthalmologist in proper intervals, visual loss can be prevented using diagnostic and therapeutic tools in a prophylactic fashion

Özet

Diabetes mellitus hem sistemik kronik metabolik bir hastalık olarak hem de mikroanjiopatik karakteriyle göz yapısındaki birçok dokuda patolojilere yol açabilmektedir. Korneal yüzey ve gözyaşı sistemini bozmakta, lenste refraktif değişiklikler ya da katarakt gelişimine yol açmakta, retinada diyabetik makulopati ve retinopatiye neden olarak ağır görme kaybına neden olabilmektedir. Diyabetik hastaların uygun aralıklarla oftalmolog tarafından takip edilmesi, diyagnostik ve terapödik uygulamaların profilaktik olarak yapılabilmesi ile görme kaybınının engellenmesi olasıdır

🔖

Cite This Article

ERDEN, B., BÖLÜKBAŞI, S., ERDENÖZ, S., ELÇİOĞLU, M. (2015). Diabetes Mellitus and Ophthalmology. Okmeydanı Tıp Dergisi, Cilt: 31 - Sayı: 0, 12–16. https://ajindex.com/articles/291751

References (7)

  1. Rehany U, Ishii Y, Lahav M, Rumelt S. Ultrastructural changes in corneas of diabetic patients: an electron- microscopy study. Cornea. 2000;19(4):534-538. http://dx.doi.org/10.1097/00003226-200007000-00026
  2. Rosenberg ME, Tervo TM, Immonen IJ, Müller LJ, Grönhagen-Riska C, Vesaluoma MH Corneal structure and sensitivity in type 1 diabetes mellitus. Invest Oph- thalmol Vis Sci 2000;41(10):2915-2921. Sánchez-Thorin JC. The cornea in diabetes mellitus. Int Ophthalmol Clin 1998;38(2):19-36. Review. http://dx.doi.org/10.1097/00004397-199838020-00004
  3. Li L, Wan XH, Zhao GH. Meta-analysis of the risk of cataract in type 2 diabetes. BMC Ophthalmol. 2014 Jul 24;14:94. http://dx.doi.org/10.1186/1471-2415-14-94
  4. Küchle M, Schönherr U, Dieckmann U. Risk factors for capsular rupture and vitreous loss in extracapsular ca- taract extraction. The Erlangen Ophthalmology Group. Fortschr Ophthalmol 1989;86(5):417-21.
  5. Klein R, Lee KE, Knudtson MD, Gangnon RE, Klein BE. Changes in visual impairment prevalence by period of diagnosis of diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy.Ophthalmology. 2009 Oct;116(10):1937-42. http://dx.doi.org/10.1016/j.ophtha.2009.03.012
  6. Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al, Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group. The effects of medical management on the progression of diabetic re- tinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 2014;121(12):2443-51. http://dx.doi.org/10.1016/j.ophtha.2014.07.019
  7. Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJ, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retino- pathy. Br J Ophthalmol 2012;96(4):587-590. http://dx.doi.org/10.1136/bjophthalmol-2011-301005 Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Gro- up. Ophthalmology 1991;98(5 Suppl):834-840 http://dx.doi.org/10.1016/S0161-6420(13)38015-4 Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 Suppl):766-785. Treatment techniques and clinical guidelines for pho- tocoagulation of diabetic macular edema. Early Treat- ment Diabetic